TRex Bio, Inc., a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, has announced a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly and Company to develop novel therapies for the treatment of immune-mediated diseases. Building upon a prior successful collaboration, this partnership is expected to bring forth groundbreaking advances in the field of immunotherapeutics.
We are thrilled to expand our partnership with Lilly and leverage TRexBio’s Deep Biology platform to develop innovative therapeutic treatments for immune-related diseases. Through this collaboration, we strive to create first-in-class therapies that will benefit patients suffering from these illnesses. Laura Berner, Chief Operating Officer of TRexBio, expressed her excitement for this partnership, saying, “We have been working closely with Lilly on these immunology programs and are thrilled to continue this successful collaboration.”
Johnston Erwin, CEO of TRexBio, is excited to announce the partnership with Lilly, a global leader in immunology. This collaboration is a testament to TRexBio’s ability to identify and characterize human Treg biology pathways, which are essential for the development of new drugs and treatments. It furthers TRexBio’s mission of providing better medicines to those in need.
Unlock the power of Treg biology with TRexBio’s Deep Biology platform! Our high-resolution sequencing of human tissue, cutting-edge computational biology tools, and scalable translational biology assay systems come together in an optimized workflow to explore the behavior of Tregs in human tissue. By mapping Treg behavior to disease processes, we unlock a powerful approach to quickly discover and functionally characterize unique targets, and rapidly advance therapeutic candidates focused on Treg biology.
TRexBio and Lilly have struck an agreement that will see TRexBio receive an upfront payment of $55 million and the potential to earn more than $1.1 billion upon the successful completion of certain development, regulatory, and commercial milestones. Additionally, TRexBio is eligible to receive tiered royalties on product sales. In exchange, Lilly has been granted an exclusive worldwide license to develop and commercialize drug candidates from three programs, taking on the responsibility for all related clinical development and commercialization costs. This transaction is subject to customary closing conditions.
TRexBio is revolutionizing the way we treat immune-mediated diseases. By combining cutting-edge computational biology tools, a deep understanding of human tissue, and expertise in immunobiology, we are developing groundbreaking therapeutics that aim to restore human tissue immune homeostasis. Our powerful Deep Biology platform maps Treg behavior to disease processes, unlocking new potential avenues of treatment. Founded in 2018 and backed by SV Health Investors, we are based in South San Francisco, California and are making great strides in the biotechnology industry.